LABU has made a top. Inflows into biotech has slowed a lot in the past few days. The market is dragging biotech higher but valuations are not helped much by improving economic outlook. That means it’s time to turn my attention to LABD. more specifically the short term swings and scalps that occur when this etf is in consolidation.